The scoringsystem usedin chronicphaseNumber ofblastspresent inacceleratedphaseNon-pharmacologicaltreatment forCMLI want toavoid thisTKI if I donot wantdiarrheaI have theT315I mutationbut also haveelevated lipaseThe current5-yearoverallsurvival rateof CMLTherecommendedcriteria usedfor acceleratedphaseThe numberof distinctclinicalphases inCMLWhen togive H2RAswithdasatinibTranslocationbetweenthese twochromosomesoccur in CMLI failed 3lines of TKIs,I can try thisagent nextModerateto highemetogenicrisk TKIsAfter 3months, I have3% BCR-ABL,I have this TKIresponse60-70% ofpatients withCML presentwith thissymptomThelandmarkfor thefirst TKIThis TKI hasthe mostmetabolicsyndromeI avoid thisdrug classwith bosutinib,nilotinib anddasatinibPercentageof blastspresent inthe blastphaseResponsewhen BCR-ABL1 (IS)is <0.01%Patients havepresence of thisBCR-ABLproteinindicative ofCML Too many ofthese bloodcells areabnormal inCMLTreatmentfor blastphaseCMLDrug classthatrevolutionizedCMLtreatmentTKIs aremajorsubstratesfor this liverenzymeThe scoringsystem usedin chronicphaseNumber ofblastspresent inacceleratedphaseNon-pharmacologicaltreatment forCMLI want toavoid thisTKI if I donot wantdiarrheaI have theT315I mutationbut also haveelevated lipaseThe current5-yearoverallsurvival rateof CMLTherecommendedcriteria usedfor acceleratedphaseThe numberof distinctclinicalphases inCMLWhen togive H2RAswithdasatinibTranslocationbetweenthese twochromosomesoccur in CMLI failed 3lines of TKIs,I can try thisagent nextModerateto highemetogenicrisk TKIsAfter 3months, I have3% BCR-ABL,I have this TKIresponse60-70% ofpatients withCML presentwith thissymptomThelandmarkfor thefirst TKIThis TKI hasthe mostmetabolicsyndromeI avoid thisdrug classwith bosutinib,nilotinib anddasatinibPercentageof blastspresent inthe blastphaseResponsewhen BCR-ABL1 (IS)is <0.01%Patients havepresence of thisBCR-ABLproteinindicative ofCML Too many ofthese bloodcells areabnormal inCMLTreatmentfor blastphaseCMLDrug classthatrevolutionizedCMLtreatmentTKIs aremajorsubstratesfor this liverenzyme

Chronic Myeloid Leukemia BINGO - Call List

(Print) Use this randomly generated list as your call list when playing the game. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
B
2
O
3
O
4
B
5
N
6
I
7
N
8
O
9
G
10
G
11
O
12
G
13
I
14
G
15
G
16
O
17
I
18
B
19
B
20
B
21
N
22
I
23
N
24
I
  1. B-The scoring system used in chronic phase
  2. O-Number of blasts present in accelerated phase
  3. O-Non-pharmacological treatment for CML
  4. B-I want to avoid this TKI if I do not want diarrhea
  5. N-I have the T315I mutation but also have elevated lipase
  6. I-The current 5-year overall survival rate of CML
  7. N-The recommended criteria used for accelerated phase
  8. O-The number of distinct clinical phases in CML
  9. G-When to give H2RAs with dasatinib
  10. G-Translocation between these two chromosomes occur in CML
  11. O-I failed 3 lines of TKIs, I can try this agent next
  12. G-Moderate to high emetogenic risk TKIs
  13. I-After 3 months, I have 3% BCR-ABL, I have this TKI response
  14. G-60-70% of patients with CML present with this symptom
  15. G-The landmark for the first TKI
  16. O-This TKI has the most metabolic syndrome
  17. I-I avoid this drug class with bosutinib, nilotinib and dasatinib
  18. B-Percentage of blasts present in the blast phase
  19. B-Response when BCR-ABL1 (IS) is <0.01%
  20. B-Patients have presence of this BCR-ABL protein indicative of CML
  21. N-Too many of these blood cells are abnormal in CML
  22. I-Treatment for blast phase CML
  23. N-Drug class that revolutionized CML treatment
  24. I-TKIs are major substrates for this liver enzyme